Gore Launches Next-Gen Affinity Solutions to Strengthen Membrane Chromatography Leadership
Published: 07 Apr 2026
Author: Deepa Pandey
W.L. Gore & Associates announced the collaboration with customized ligand partners to launch an innovative range of high-performance affinity membrane chromatography products. This initiative strengthens Gore’s presence in the bio-processing sector beyond protein A-based solutions to advance purification performance and scalability for biopharmaceutical manufacturers.
W.L. Gore & Associates, Inc., based in Newark, DE, is collaborating to integrate partner-developed ligand technologies with its proven membrane platform. This platform provides innovative purification solutions across a broad range of biotherapeutic modalities. It offers a highly scalable, intensified purification system that delivers reliable performance from R&D and process development to clinical bioprocessing, with GMP-scale manufacturing and high binding capacity at fast residence times.
Russ Hornung, a business development manager at Gore, stated, “At Gore, we are committed to helping our customers accelerate the discovery, development, and delivery of vital therapies. By working with customized ligand partners, we’re combining complementary expertise to bring advanced membrane-based affinity solutions to market and expand our role in downstream processing beyond only Protein A technology.”
According to the Precedence Research, the affinity chromatography market size accounted for USD 3.90 billion in 2025 and is predicted to increase from USD 4.24 billion in 2026 to approximately USD 8.98 billion by 2035, expanding at a CAR of 8.70% from 2026 to 2035 due to the increasing demand for monoclonal antibodies and vaccines, massive investment in R&D, and introduction of high-purity and scalable purification technologies.
The new products from Gore are designed to improve purification, productivity, scalability, and cost-effective solutions to reduce potential risk across applications like cell and gene therapies, highly specialized antibody-based therapy, and more. Ligand partners of Gore will market and distribute the affinity of membrane devices with their respective brands that ensure broad accessibility and consumer support across the globe.
A recent report by Precedence Research highlights that the affinity chromatography market is benefiting from rapid advancements in resin technology and the adoption of automated, cost-efficient purification methods.